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Abstract
SF3B1 is the most frequently mutated splicing factor in cancer. Mutations in SF3B1 likely con-
fer clonal advantages to cancer cells but they may also confer vulnerabilities that can be thera-
peutically targeted. SF3B1 cancer mutations can be maintained in homozygosis in C.
elegans, allowing synthetic lethal screens with a homogeneous population of animals. These
mutations cause alternative splicing (AS) defects in C. elegans, as it occurs in SF3B1-mutated
human cells. In a screen, we identified RNAi of U2 snRNP components that cause synthetic
lethality with sftb-1/SF3B1 mutations. We also detected synthetic interactions between sftb-1
mutants and cancer-related mutations in uaf-2/U2AF1 or rsp-4/SRSF2, demonstrating that
this model can identify interactions between mutations that are mutually exclusive in human
tumors. Finally, we have edited an SFTB-1 domain to sensitize C. elegans to the splicing mod-
ulators pladienolide B and herboxidiene. Thus, we have established a multicellular model for
SF3B1 mutations amenable for high-throughput genetic and chemical screens.
Author summary
SF3B1 encodes a splicing factor frequently mutated in hematological malignancies, and
with less frequency in other solid tumors. Each SF3B1 mutation is predominant in a can-
cer type, indicating cell type-specific pathogenic mechanisms. We have reproduced three
cancer-related SF3B1 missense mutations in the C. elegans ortholog sftb-1 and they do not
cause any overt phenotypes, but few alterations in splicing. However, the combination of
these mutations has additive effects, hampering SFTB-1 functions and allowing the study
of synthetic interactions that may result in a defective spliceosome structure. As a result of
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an RNAi screen, we identified other proteins of the U2 snRNP complex as targets for syn-
thetic lethality. The sftb-1 mutant strains also allow the identification of mutations in
other splicing factors that are mutually exclusive with SF3B1 mutations in tumors. SF3B1
cancer mutations are heterozygous, and interestingly, the most promising therapeutic
venue is based on pladienolide B (PB) derivatives that hit the wild-type and the mutated
protein. We have edited SFTB-1 to sensitize it to pladienolide B and herboxidiene (HB),
therefore making C. elegans suitable for assaying the toxicity and efficacy of their chemical
derivatives. Thus, our model represents a pre-clinical system for investigating both syn-
thetic lethality and chemotherapies. Besides that, we have generated the first C. elegans
strain in which splicing can be chemically modulated by PB and HB.
Introduction
Deregulated RNA splicing is emerging as a new hallmark of cancer following the discovery of
several splicing factor genes harboring somatic mutations in different tumor types [1]. SF3B1,
a core component of the U2 snRNP, is the most frequently mutated splicing factor in human
cancers. Somatic heterozygous mutations in SF3B1 are particularly prevalent in myelodysplas-
tic syndromes (MDS)—up to 80% in refractory anemia with ring sideroblasts [2–4]; and in
15% of chronic lymphocytic leukemia (CLL) [5–7]. SF3B1 mutations have also been reported
in solid tumors, including 20% of uveal melanomas (UM) [8–10], 3% of pancreatic ductal ade-
nocarcinomas [11], and 1.8% of breast cancers [12]. RNA-sequencing (RNA-seq) analyses in
different tumor types and cell lines with SF3B1 missense mutations, including the most preva-
lent substitution K700E, identified distinct alternative splicing (AS) defects [13–15].
Recently, CRISPR/Cas9 genome editing has allowed researchers to faithfully reproduce
human pathological mutations in animal models. Human SF3B1 mutations have been intro-
duced in cell lines [15–18], but mimicking these mutations in multicellular organisms has only
been achieved by conditional alleles in murine models [19]. Taking advantage of the extraordi-
nary conservation of splicing factors across evolution and the ease of genetic manipulation of
C. elegans, we established a multicellular model to study SF3B1 cancer-related mutations. Spli-
ceosome components, and particularly SF3B1, are being intensively studied as targets of anti-
tumor drugs [20–22]. Some natural compounds modulate splicing by targeting SF3B1. Among
them, pladienolide B is particularly relevant because H3B-8800, a PB derivative, has antitu-
moral effects and is in clinical trials [23]. The modulatory activity of PB is highly dependent on
SF3B1 structure, and single amino acid substitutions cause resistance to PB [24,25]. Hence,
particular residues in the drug binding site that are not conserved in SFTB-1 may confer resis-
tance to PB in worms, as it has been recently observed in yeast [26]. We edited four amino
acids to humanize the HEAT repeat 15 in SFTB-1, making C. elegans sensitive to splicing mod-
ulators. Thus, we have created the first C. elegans strain sensitive to PB and HB, which would
facilitate the chemical modulation of splicing in this model system.
Altogether, the multicellular model of SF3B1 mutations described in this study provides a new
pre-clinical platform for identifying new targets and small molecules for use in cancer therapies.
Results
sftb-1, the C. elegans ortholog of SF3B1, is a ubiquitously expressed gene
essential for development
The C. elegans protein SFTB-1 is 66% identical to human SF3B1 in terms of amino acid com-
position. Homology is particularly high at the HEAT domain, reaching 89% identity, and the
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most frequently mutated amino acids in cancer are conserved. The SFTB-1 sequence also con-
serves some of the U2AF ligand motifs (ULMs) that bind U2AF homology motifs (UHMs)
present in other splicing factors (Figs 1A and S1) [27].
As expected for a core splicing factor, the CRISPR-engineered endogenous fluorescent
reporter mCherry::SFTB-1 showed ubiquitous expression in somatic and germ cells, being
absent in mature sperm only (Fig 1B and 1C). We also used CRISPR to generate the sftb-1
(cer6) mutation, a deletion allele that produces a premature stop codon (S2 Fig) and causes an
arrest at early larval stages, confirming that sftb-1 is essential for development (Fig 1D and 1E).
sftb-1(cer6) homozygous animals completed embryonic development but arrested as larvae
that could undergo few germ cell divisions (S2 Fig). Since embryos depleted of sftb-1 tran-
scripts are not viable [28], our observation indicates that maternal wild-type (WT) product
can still be present in the early larva. We formally tested this hypothesis by combining the sftb-
1 deletion allele and the sftb-1 endogenous mCherry reporter in the same strain (S2 Fig). The
compound heterozygotes produced a normal brood size and segregated 19.39% non-red cer6
homozygotes (S2 Fig). By monitoring mCherry::SFTB-1 expression in the progeny of hetero-
zygous mothers, we observed a small percentage of early L1 larvae with dim red fluorescent
expression that later became non-red and developmentally arrested larvae (S2 Fig), indicating
that there is some SFTB-1 maternal product reaching the early L1 stage.
Different sftb-1 missense mutations display additive effects when combined
We edited the C. elegans genome to mimic the K700E mutation, the most frequent SF3B1 sub-
stitution in tumors. sftb-1[K718E] homozygous animals did not display any obvious pheno-
types. Thus, we decided to reproduce two other SF3B1 cancer-related mutations. R625C is a
particularly prevalent mutation in uveal melanoma, and Q534P is less common but is pre-
dicted to have a strong impact on SF3B1 structure due to its location in an α-helix [29]. Similar
to sftb-1[K718E], the two additional missense mutations, sftb-1[R643C] and sftb-1[Q552P] (S3
Fig), did not cause any evident phenotypes in C. elegans.
We were interested in producing animals with defective sftb-1 function resulting in a viable
and traceable phenotype for investigating modifiers of altered SFTB-1 activity. Since the effects
of MDS-related missense mutations were reported to be additive in the yeast SF3B1 ortholog
Hsh155 [30], we generated three strains with each of the possible pairs of mutations: sftb-1
[R643C, K718E], sftb-1[Q552P, K718E], and sftb-1[Q552P, R643C]. None of the three double
mutants showed an obvious phenotype. However, animals simultaneously carrying the three
missense mutations sftb-1[Q552P, R643C, K718E] displayed several temperature-sensitive
developmental defects including partial sterility, protruding vulva, and developmental delay
(Figs 1F–1H and S3). These results suggest that each of the three missense mutations provokes
a functional impact that becomes unmasked only when the three mutations are combined.
Distinct sftb-1 alleles produce alterations in alternative splicing and gene
expression
The most commonly described AS defect caused by cancer-associated SF3B1 mutations is the
incorrect recognition of 3’ splice sites, producing aberrant transcripts [13,14,18,31,32]. We
investigated in C. elegans the transcriptional consequences of the K718E mutation, an equiva-
lent of the most frequent SF3B1 mutation K700E, by RNA-seq of two different strains with
two independent K718E alleles (cer3 and cer7) and their WT siblings at the L4 stage. Then, we
used rMATS for robust detection of differential AS events between mutant and WT worms
[33]. Using both splice junction and exon body reads, our analysis detected 21,985 AS events,
of which 134 were significantly altered (FDR < 0.05) (S1 Table). A more restricted cut-off
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(inclusion level difference > 0.1), similar to that used in a previous rMATS analysis of SF3B1-
mutated samples [32], reduced the list of significant AS events to 78, with skipped exon (SE)
being the most frequent event (Fig 2A and 2B).
Then, we investigated whether the two sftb-1 alleles associated with a visible phenotype (the
triple mutation allele cer39, and the deletion allele cer6) primarily induced cryptic 3’ splice site
selection. It is worth noting that, in this experiment, larvae were harvested and processed for
RNA isolation at the L2 stage to avoid possible indirect effects due to developmental defects
observed after this stage. Both alleles were associated with a high number of deregulated AS
events as determined by rMATS, and the predominant alteration was also exon skipping (Fig
2B).
We then explored if there were differentially expressed protein-coding (Fig 2C) and non-
coding (Fig 2D) transcripts in the three RNA-seq datasets (S2 Table). As expected, the highest
number of significantly altered transcripts was observed in the cer6 allele.
A functional enrichment analysis uncovered biological pathways that were significantly
affected by the distinct sftb-1 alleles (S4 Fig). The K718E mutation caused the downregulation
of transcripts related to mitochondrial functions, which were also downregulated by the dele-
tion allele cer6. Both cer39 and cer6 alleles induced the upregulation of transcripts involved in
mRNA processing, and the downregulation of different metabolic pathways. Thus, it seems
that the common reaction to an impaired splicing is to increase the splicing components and
reduce the metabolism.
Interestingly, there is a partial overlap between the transcripts deregulated by the triple
mutation allele cer39 and the deletion allele cer6 (Fig 2E). We also found few AS events that
are similarly altered in distinct sftb-1 mutants. The largest overlap was again observed between
the cer39 and the cer6 alleles, which shared 80 deregulated events (S5 Fig). Thus, the additive
effect of three missense mutations produces a similar impact on gene expression as the dele-
tion allele but with a considerable number of unique AS changes.
In summary, we identified gene expression and AS alterations that are more frequent as
sftb-1 function becomes progressively compromised, with SE being the predominant AS
defect.
A subset of U2 snRNP and U2-associated components synthetically
interacts with sftb-1 mutants
In the search for selective vulnerabilities in sftb-1 defective backgrounds, we hypothesized that
sftb-1 mutant animals would be more sensitive to knockdown of other splicing factors than
their WT counterparts. Based on a previous C. elegans RNA interference (RNAi) collection of
Fig 1. Characterization of sftb-1, the C. elegans ortholog of SF3B1, and different sftb-1 mutations. (A) Number of SF3B1 missense mutations annotated in
COSMIC database [75] at each amino acid position, with labels placed on the relevant residues for this study. A schematic structure of the SF3B1 protein is shown
below, where purple, yellow, and blue boxes represent the U2AF ligand motifs (ULMs), the p14-interacting region, and the 20 HEAT repeats, respectively. The bars at
the bottom line indicate residues that are conserved in the C. elegans protein. (B) Representative image of an embryo, L2, and L4 larvae with mCherry::SFTB-1
endogenous expression. The fluorescence image (top panel) is merged with the corresponding differential interference contrast (DIC) image (bottom panel). (C)
Fluorescence images of dissected gonads from adult worms expressing mCherry::SFTB-1. Gonads were stained with DAPI to visualize nuclei. Insets show
differentiated sperm nuclei, where mCherry::SFTB-1 is not expressed. (D) Left: diagram depicting how the cer6 deletion allele is maintained in heterozygosis. The WT
sftb-1 copy is genetically linked to a red fluorescent marker (oxTi615). Right: worm body length of WT and heterozygotes (red, n = 475), and cer6 homozygotes (gray,
n = 134) grown for 48 h at 20˚C (N = 3). (E) Representative image of synchronized red and non-red siblings after growing for 48 h at 20˚C. (F) Incidence of different
sftb-1[Q552P, R643C, K718E] phenotypes at 25˚C. Dots represent percentages observed in each replicate (n = 119, 116; N = 2). (G) Brood size of WT or sftb-1
[Q552P, R643C, K718E] fertile worms at 25˚C (n = 22, 35; N = 2). (H) sftb-1[Q552P, R643C, K718E] animals display developmental delay at 25˚C. The proportion of
the population at each stage is represented by the size of the dots (n = 119, 116; N = 2). In (D) and (G), dots represent measures in individual worms, and overlaid
Tukey-style boxplots represent the median and interquartile range (IQR). Whiskers extend to the minimum and maximum values or at a maximum distance of
1.5xIQR from the box limits. Statistics: (D) and (G), Mann-Whitney’s test; (F), Fisher’s exact test. n.s., no significant difference, ���� p<0.0001. Scale bars: 100 μm (B
and E), 10 μm (C).
https://doi.org/10.1371/journal.pgen.1008464.g001
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Fig 2. Different sftb-1 mutations induce alternative splicing and gene expression alterations. (A) Types of AS events. Gray
boxes represent constitutive exons, while colored boxes represent alternatively spliced exons. (B) Total number of significant
(FDR<0.05) AS alterations detected by rMATS with an inclusion level difference> 0.1. Event types are color coded as in panel A.
Light colors represent AS events that were significantly more included in WT samples, while dark colors symbolize splicing
alterations associated to mutant samples. Inset doughnut charts show the distribution of significant events by event type. In the
three mutants, skipped exon (SE) was the most predominant alteration. (C) MA-plots displaying changes in protein-coding
transcript expression levels (corrected log2 fold change) over the mean of normalized counts, analyzed by DESeq2. Significant
transcripts (padj<0.05) are colored in blue. (D) MA-plots of expression changes in non-coding transcripts, represented as in panel
C. Transcripts that are significantly deregulated are colored by transcript type. (E) Venn diagrams showing the overlap between
transcripts that are upregulated (left) or downregulated (right) in the three datasets. The number of transcripts at the intersections
is shown, as well as the total number of significantly up- or downregulated transcripts in each mutant strain (padj<0.05).
https://doi.org/10.1371/journal.pgen.1008464.g002
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splicing factors [34], we compiled and assayed a total of 104 RNAi clones targeting proteins
that act in different steps of the splicing reaction. This led us to identify 27 splicing factors
whose knockdown phenotype was enhanced in at least one of the three sftb-1 single mutants,
suggesting possible synthetic interactions. Among the potential candidates, we identified pro-
teins present in pre-catalytic and catalytic spliceosomes, as well as few auxiliary factors, indi-
cating that sftb-1 missense mutations might impact other steps of the splicing reaction besides
early spliceosome assembly (S3 Table).
We selected three U2 snRNP components, including sftb-1, and two U2-associated proteins
for further validation based on their presence in the U2 snRNP and the phenotypes observed
(Fig 3A). The identification of sftb-1 as a candidate certified our approach since it demon-
strated that any RNAi affecting sftb-1-related functions would have a stronger effect on sftb-1
mutants. Since a partial loss-of-function mutant for the candidate teg-4 was available, we pro-
ceeded to validate the interaction between sftb-1 mutations and teg-4, the C. elegans ortholog
of SF3B3, which physically interacts with SF3B1 HEAT repeats 3, 5, and 6 [29]. We found that
the K718E mutation exacerbated the phenotype of teg-4(oz210) at 20˚C [35], whereas the
Q552P mutation did so to a lesser extent (Fig 3B).
Then, we validated the rest of the candidates using RNAi. As we had observed that sftb-1
mutations had an additive effect (Fig 1F–1H), we reasoned that sftb-1 double mutants might
be more sensitive to splicing perturbations than single mutants. Consistently, sftb-1(RNAi) led
to an additive loss of function in double mutants, which arrested at earlier stages compared to
WT worms (Fig 3C). A similar result was obtained with knockdown of uaf-2/U2AF1 (Fig 3D),
another candidate from the RNAi screen.
Among the remaining U2 and U2-associated candidates, we selected mog-2/SNRPA1 and
smr-1/SMNDC1 for further validation in the double-mutation backgrounds. Strikingly,
whereas RNAi of mog-2 resulted in very low penetrant sterility in WT worms, the incidence of
the phenotype incremented to over 70% in the three sftb-1 double-mutation strains (Fig 3E). A
similar synthetic phenotype was observed upon knockdown of smr-1 (Fig 3F). Finally, sftb-1
double mutants were more sensitive to teg-4(RNAi) (Fig 3G). This former synthetic interaction
was not as strong as the one observed with mog-2(RNAi) and smr-1(RNAi) but was supported
by the interaction between genetic alleles (Fig 3B).
We also found that heterozygous animals carrying the deletion allele sftb-1(cer6) were sensi-
tive to RNAi of the five interactors (S6 Fig). Still, double mutant strains are better than cer6
heterozygous animals for identifying genetic interactions (Figs 3 and S6).
Together, our results suggest that targeting other splicing factors such as SF3B3 to compro-
mise their function can be an opportunity to selectively impair cancer cells harboring SF3B1
mutations.
The C. elegans mutations equivalent to human U2AF1S34P and SRSF2P95H
genetically interact with sftb-1[Q552P, R643C, K718E] mutants
Along with SF3B1 mutations, recurrent missense mutations in U2 small nuclear RNA auxiliary
factor 1 (U2AF1) and serine/arginine-rich splicing factor 2 (SRSF2) were discovered in hemato-
logical malignancies [2], and later reported to be present in some solid tumors [36,37]. Somatic
hotspot mutations in these three splicing factors are only found in heterozygosis and are mutually
exclusive, suggesting redundant functional impact or limited tolerance to splicing perturbations.
Missense mutations in U2AF1 are commonly found at position S34, which corresponds to
a residue located within the two zinc finger domains through which U2AF1 interacts with the
pre-mRNA [38]. Similarly, SRSF2 is typically mutated at position P95, mainly bearing mis-
sense mutations but also in-frame insertions or deletions [2].
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Fig 3. Synthetic interaction between sftb-1 mutant strains and knockdown of U2 snRNP and U2 snRNP-related
components. (A) Schematics of the RNAi screen. In brief, WT or mutant worms bearing any of the three sftb-1 single
mutations were fed with RNAi clones against a total of 104 splicing factors. 77 clones had the same effect in all genetic
backgrounds. In contrast, we identified 27 clones that caused a stronger phenotype in at least one of the three single mutant
strains compared to WT, which was indicative of a synthetic interaction. Listed are the 3 U2 snRNP and 2 U2 snRNP-
related candidates from the screen that were selected for further validation. (B) sftb-1[K718E] and sftb-1[Q552P]
synthetically interact with teg-4(oz210). The number of hatched larvae (orange) and dead embryos (gray) laid by worms of
the indicated genotype at 20˚C is represented (n�28; N = 3). m+ z-, homozygous mutant progeny of heterozygous mothers.
No significant differences were observed in the number of hatched larvae laid by sftb-1[K718E], sftb-1[R643C], and sftb-1
[Q552P] compared to WT. (C) Worm length after 48 h of RNAi treatment against gfp (black) or sftb-1 (blue) at 25˚C
(n�150; N = 2). (D) Worm length after 48 h of RNAi treatment against gfp (black) or uaf-2 (blue) at 25˚C (n�150; N = 2).
In both (C) and (D), worm length was not significantly different between sftb-1 mutants and WT upon gfp(RNAi). (E-G)
Mean percentage of sterile worms observed upon RNAi of mog-2 (E; n�30), smr-1 (F; n�27) and teg-4 (G; n�34) at 25˚C.
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Based on a recently reported synthetic interaction between Srsf2P95H/+ and Sf3b1K700E/+ in
mice [39], and on the fact that sftb-1 mutants were more sensitive to inactivation of some splic-
ing factors (Fig 3), we wondered if the combination of sftb-1[K718E] with mutations equiva-
lent to U2AF1S34F or SRSF2P95H would be tolerated in C. elegans.
Thus, we edited the worm orthologs of these genes to generate the uaf-2[S42F] and rsp-4
[P100H] mutant strains. Neither of these two mutations caused any obvious phenotypes nor
dramatic changes in some AS events analyzed by RT-PCR (S7 Fig). In contrast to its murine
counterpart Srsf2P95, rsp-4[P100H] is tolerated in homozygosis [39].
We did not detect any interaction when combining each of these mutants with sftb-1
[K718E] or the three sftb-1 double-mutation strains. In contrast, rsp-4[P100H] and uaf-2
[S42F] significantly increased the low percentage of sterile worms observed in the sftb-1
[Q552P, R643C, K718E] background at 20˚C (Fig 4A). The most dramatic effect was observed
by the addition of the uaf-2[S42F] mutation to the sftb-1 triple-mutation strain.
As a result of these synthetic interactions, we observed masculinization of the germline
(Mog) and tumorous germline (Tum) phenotypes, which are hallmarks of germlines with
altered splicing activity [34]. Thus, these synthetic interactions may cause a synergistic disrup-
tion of general splicing functions, perhaps through a flaw in spliceosomal architecture,
although detailed information on the molecular basis of this interaction should be obtained by
deep sequencing of mutant transcriptomes.
Moreover, this combination of uaf-2 and sftb-1 mutations induced developmental delay at
20˚C (Fig 4B). These results show for the first time in an animal model a synthetic interaction
between sftb-1 and uaf-2 missense mutations.
A humanized HEAT repeat 15 in SFTB-1 sensitizes C. elegans to
pladienolide B and herboxidiene
The SF3B1 C-terminal region contains 20 structural motifs known as HEAT repeats, each one
formed by two alpha helices joined by a short loop. These motifs display some structural plas-
ticity and are involved in interactions with the pre-mRNA and other proteins [29]. Specific
residues within SF3B1 HEAT repeats 15, 16, and 17 (H15–H17) interact with PB [40], and
some amino acids in this region are not conserved in C. elegans (Fig 5A). In order to test if
these sequence differences would affect the worms sensitivity to splicing modulators, we
exposed WT animals and sftb-1 cancer-related mutants to PB and to the synthetic molecule
sudemycin D6 [41], which also targets the SF3B complex. Both drugs had no visible effects
when delivered in liquid medium or via microinjection (S4 Table). To reproduce the PB bind-
ing site in sftb-1, we used CRISPR to introduce four missense mutations (cer144 allele) that
mimic the human HEAT repeat 15 (Fig 5B). The resulting strain was apparently WT but
became sensitive to PB, although the substitutions were not enough to overcome the resistance
to sudemycin D6. sftb-1(cer144) mutant larvae exposed to 10, 50, and 100 μM PB displayed a
dose-dependent growth defect (Fig 5C). In addition, humanization of the HEAT repeat 15 also
conferred sensitivity to herboxidiene (HB) (also known as GEX1A) (Fig 5D), which is pre-
dicted to be accommodated in the H15-H17 pocket similarly to PB [40,42].
Red dots indicate percent sterility observed in each replicate (N = 2). Gray bars, P0-treated worms giving rise to<5 F1
larvae and some dead embryos (‘dead progeny’ category); black bars, P0-treated worms that laid neither larvae nor dead
embryos (‘no progeny’ category). In (B), (C), and (D), data are shown as Tukey-style boxplots and overlaid dots
representing measures in individual animals. Statistics: (B), (C), and (D), Kruskal-Wallis test with Dunn’s multiple
comparison test. Data were compared to teg-4(oz210) (B), or to WT animals fed with the same RNAi clone (C) and (D).
(E-G), Fisher’s exact test with Bonferroni correction for multiple comparison. � p<0.05, �� p<0.01, ��� p<0.001, ����
p<0.0001.
https://doi.org/10.1371/journal.pgen.1008464.g003
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Discussion
SF3B1 cancer-related mutations have been intensively studied in the past few years. They are
particularly recurrent in MDS or UM, which commonly lack effective therapeutic approaches.
In this study, we establish the first multicellular model for SF3B1 mutations expressed non-
conditionally from the endogenous locus. The rapid C. elegans life cycle (three days at 25˚C)
and the around 300 self-progeny obtained from a single hermaphrodite, among other features,
make this model organism ideal for large-scale genetic and drug screens. The task of modeling
human pathological mutations has been facilitated by the advent of the CRISPR/Cas9 genome
editing technique, which has been efficiently implemented in this nematode [43,44].
As expected for a core splicing factor, and as previously reported in zebrafish [45] and mice
[46], the C. elegans SF3B1 ortholog is essential for development. Cancer cells bear SF3B1 hot-
spot mutations in heterozygosis and depend on SF3B1 WT function for viability [47]. How-
ever, homozygous sftb-1 missense mutations are viable in C. elegans, although they generate
defects that are unmasked when additional alterations in the spliceosome are introduced.
Such a feature is advantageous for investigating vulnerabilities of SF3B1-mutated tumors,
which are not only conferred by missense mutations, but also by the loss of one SF3B1 WT
copy [16,48].
Differently from MDS with SF3B1 mutations, where aberrant transcripts have been directly
related to phenotypic traits [32,49], transcripts affected by sftb-1[K718E] do not produce any
obvious phenotypes. Still, Sf3b1K700E/+ murine models only partially recapitulate the hemato-
poietic phenotype characteristic of MDS [50,51] and CLL [52], although a modest overlap in
Fig 4. Genetic interaction between rsp-4/SRSF2, uaf-2/U2AF1, and sftb-1 mutant strains. (A) Mean percentage of sterile worms of the indicated genotype at 20˚C
(N = 2). Black dots denote observed values in each replicate. Statistical significance was determined with the Fisher’s exact test with Bonferroni correction for
multiple comparison. Lines indicate compared groups. �� p<0.01, ���� p<0.0001. (B) rsp-4[P100H] and uaf-2[S42F] mutations gradually exacerbate the mild
developmental delay displayed by the sftb-1[Q552P, R643C, K718E] mutant at 20˚C. Dot sizes symbolize the percentage of worms at each developmental stage on
any given day. In both panels, n�110, N = 2.
https://doi.org/10.1371/journal.pgen.1008464.g004
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Fig 5. Humanization of the SFTB-1 HEAT repeat 15 confers sensitivity to pladienolide B and herboxidiene. (A) Protein sequence alignment of residues in
HEAT repeats 15 and 16. Amino acids that differ between worm SFTB-1 (Ce) and human SF3B1 (Hs) are colored in green. Positions of these residues in the human
sequence are indicated. (B) CRISPR/Cas9 design to “humanize” the SFTB-1 HR15. In the wild-type allele, the crRNA sequence used is indicated by orange
nucleotides, and the protospacer-adjacent motif (PAM) is underlined. In the mutant (“humanized”) allele, synonymous mutations introduced to prevent partial
recombination events and to improve primer specificity for mutant allele detection by PCR are indicated in blue. Missense mutations and the corresponding amino
acids are colored in green. (C) Worm length after 48 h of drug treatment at 25˚C (n�120; N = 3). WT animals are represented as black dots, and sftb-1(cer144)
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aberrant splicing events between Sf3b1K700E/+ mice and MDS patients with SF3B1 mutations
was detected [39].
RNA-seq of sftb-1[K718E] animals did not identify the aberrant use of alternative 3’ splice
sites (A3’SS) as the predominant splicing defect caused by this mutation, as has been observed
in human cells [13,14,16,18,31,32,52,53]. Indeed, in three distinct sftb-1 mutants, we found a
mild effect on AS, with SE being the most abundant splicing defect. Such disparity in the con-
sequences of the K700E mutation between humans and nematodes may be explained by differ-
ent factors. First, diverse computational pipelines have been used to assess differences in
alternative splicing between WT and SF3B1-mutated samples, resulting in distinct conclu-
sions. For instance, Liberante and coworkers reanalyzed previously published data and found
that SF3B1 mutation was mostly associated with differential skipped exon events, rather than
A3’SS selection [15]. Second, intronic elements directing splicing have evolved differently in
C. elegans compared to other organisms. C. elegans introns are typically shorter, do not have a
consensus branch site (BS) sequence, and the vertebrate polypyrimidine (Py) tract is replaced
by the consensus UUUUCAG/R sequence [54]. Third, only ~35% of genes are alternatively
spliced in C. elegans [55] compared to 95% in humans [56]. Fourth, cell type-specific alterna-
tive isoforms generated by sftb-1 mutations could have been underrepresented in our analyses
as we sequenced the transcriptome of whole animals, and A3’SS selection can be regulated in a
tissue-specific manner in C. elegans [57]. And fifth, the nonsense-mediated decay (NMD) sys-
tem could efficiently eliminate transcripts with A3’SS resulting from sftb-1 mutations, as
occurs in human cells [13]. However, we did not detect predominance of downregulation
among the differentially expressed transcripts (Fig 2C and 2D).
Beyond its action on A3’SS usage, SF3B1 missense mutations could have an impact on the
structure, the interaction with other proteins in the spliceosome, or the robustness of the pro-
tein. In fact, the PB derivative H3B-8800, which induces lethality in spliceosome-mutant can-
cers by modulating the SF3B complex, affects AS activity similarly in WT and in SF3B1K700E
human cells [23]. Therefore, SF3B1-mutated cells present vulnerabilities that can be exploited
in synthetic lethal screens. We found that sftb-1 mutants are sensitive to RNAi of different
splicing factors, including itself, and we further validated these synthetic interactions with the
inactivation of other components of the U2 snRNP. These results point to other components
of the spliceosome as targets to preferentially kill cells with deficiencies in SF3B1 activity.
Knowing the suitability of sftb-1 mutants for RNAi screens, the collection of RNAi clones to be
tested should be expanded, with particular interest placed on deubiquitinases and chromatin
factors that have been related to SF3B1 functions [48,58].
Pladienolide and related compounds have been proven to be effective in selectively killing
cells with SF3B1 mutations [23,50,59]. We tested pladienolide B and sudemycin D6 in WT ani-
mals and sftb-1 cancer-related mutants but did not observe any effects (S4 Table). The modula-
tory activity of these drugs is highly dependent on the protein structure, as evidenced by the
fact that missense mutations in SF3B1 confer resistance to the drugs [24,25]. By modifying
four amino acids, we reproduced the human HEAT repeat 15 in C. elegans SFTB-1. As a result,
worms became sensitive to pladienolide B and herboxidiene but maintained resistance to sude-
mycin D6. Further humanization of SFTB-1 and other SF3B complex components would
mutants as green dots. Doxycycline treatment induced larval arrest in both strains and was used as positive control. Data are shown as Tukey-style boxplots and
overlaid dots represent measures in individual animals. The horizontal line at 1000 μm indicates the expected body length of an adult worm. Body length of mutant
worms treated with 50 μM doxycycline and 10 μM and 50 μM PB differed statistically from that of mutant worms treated with 0.5% DMSO (p<0.0001). The same
applied when comparing mutant worms treated with 100 μM PB and 1% DMSO. Significance was determined with the Kruskal-Wallis test with Dunn’s multiple
comparison test. (D) Worm length after 48 h of herboxidiene or doxycycline (control) treatment at 25˚C (n�139; N = 3). Data are represented and analyzed as in
panel C (n.s., no significant difference).
https://doi.org/10.1371/journal.pgen.1008464.g005
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likely increase the sensitivity to these drugs and expand the number of known splicing modu-
lators effective in C. elegans. As an example, while PHF5A is highly conserved in C. elegans, the
Y36 position, which confers resistance to PB, HB, and sudemycin D6 when mutated [25], cor-
responds to a histidine. Thus, the H36Y substitution in C. elegans might increase sensitivity to
splicing modulators.
It is worth mentioning that this is the first report of an invertebrate animal model sensitive
to PB and HB. Previously, splicing inhibition by PB in vivo was reported in yeast strains that
were edited to humanize some Hsh155 HEAT repeats and mutated to block PB efflux [26]. As
an added value to the C. elegans toolkit, we have generated a strain that presents WT character-
istics but is sensitive to splicing modulators such as PB and HB, which we believe has great
potential for splicing-related studies in this nematode.
SF3B1 mutations are mutually exclusive with other splicing factor mutations present in
tumors. U2AF1 and SRSF2 missense mutations are reported in 11% and 12–15% of MDS,
respectively [19], and very rarely overlap with SF3B1 mutations, which are present in 17–28%
of MDS patients [37,39]. Hence, cells may not handle all the AS defects produced by the
combination of mutations in any of these three proteins. To further validate our model as a
tool for identifying vulnerabilities in cells with compromised SF3B1 function, we mimicked
U2AF1S34F and SRSF2P95H mutations in C. elegans and detected a functional interaction
between both mutants and the sftb-1[Q552P, R643C, K718E] allele. Additionally, C. elegans
rsp-4 and uaf-2 missense mutations could be used for RNA-seq analyses and RNAi screens to
study the consequences and vulnerabilities of these mutations, respectively.
We have demonstrated that C. elegans can be a valuable model to explore vulnerabilities of
cells with mutations in SF3B1, although the molecular consequences of sftb-1 mutations were
different from the ones observed in other organisms. Replacement of several HEAT repeats in
yeast Hsh155 with their human counterparts is functional and supports splicing [60]. Simi-
larly, partial or total replacement of sftb-1 with its human ortholog could result in a more accu-
rate model. To date, only one human gene has been functionally transplanted to C. elegans
[61], in part due to low efficiencies of inserting long DNA fragments by CRISPR. Such techni-
cal difficulties can now be bypassed by the use of Nested CRISPR [62]. Thus, humanized sftb-1
nematodes obtained by this method would be very efficient as in vivo models to further under-
stand the impact of SF3B1 mutations in cancer and as a platform for large-scale genetic and
pharmacological screens.
Materials and methods
Caenorhabditis elegans strains
C. elegans strains were maintained using standard methods [63,64] at the specified tempera-
ture. Before conducting the experiments, strains were grown for at least two generations at the
experimental temperature. Unless otherwise specified, we used Bristol N2 as the WT strain.
Mutant strains with single sftb-1 missense mutations (CER218, CER220, CER236, and
CER238) were outcrossed x2. WT siblings resulting from the second outcross were given spe-
cific strain names (CER217, CER221, CER237, and CER239, respectively) and kept for closer
comparison. CER351, CER442, and CER450 strains were outcrossed x2. In order to maintain
the cer6 deletion, heterozygous mutants were crossed with the EG7893: oxTi615 unc-119(ed3)
III strain so that a red fluorescent marker was inserted 0.15 cM away from the sftb-1 WT locus.
To study the lasting of maternally inherited SFTB-1, we made the compound heterozygous
strain CER505: sftb-1(cer6/cer114[mCherry::sftb-1]) III. All the strains used in this study are
listed in S5 Table.
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Protein alignments
H. sapiens SF3B1 (Uniprot: O75533) and C. elegans SFTB-1 (Uniprot: G5EEQ8) protein
sequences were aligned using the T-Coffee algorithm [65] with default settings. S1 Fig was gen-
erated with Jalview [66].
CRISPR/Cas9 mutant and reporter strains
Specific guide RNAs were designed using both Benchling (www.benchling.com) and CCTop
[67] online tools. All CRISPR/Cas9 mutant and reporter strains were obtained following a co-
CRISPR strategy [68] using dpy-10 as a marker to enrich for genome-editing events. In all
cases, mixes were injected into gonads of young adult P0 hermaphrodites using the Xeno-
Works Microinjection System and following standard C. elegans microinjection techniques. F1
progeny was screened by PCR using specific primers and F2 homozygotes were confirmed by
Sanger sequencing. As we optimized the protocol for CRISPR/Cas9 genome editing in our lab-
oratory while preparing this manuscript, different reagents and conditions were used to pro-
duce the distinct mutants. The sftb-1(cer6) deletion mutant allele was obtained by nonspecific
double-strand break repair on our first attempt to generate the K718E mutation. Only in this
experiment, guide RNAs and Cas9 were expressed from plasmids that were purified with the
NucleoBond Xtra Midi Kit (Macherey-Nagel). In the remaining mixes, ribonucleoprotein
complexes containing crRNA, tracrRNA, and Cas9 were annealed at 37˚C for 15 minutes
prior to injection. All the reagents and injection mixes used in this study are listed in S6 Table.
C. elegans microscopy
Worms were mounted on 2% agar pads with 10 mM tetramisole hydrochloride and imaged
using a ZEISS Axio Observer Z1 inverted fluorescence microscope. Images were processed
using ZEISS ZEN 2012 (blue edition) software and Fiji.
Gonad dissection and DAPI staining
Worms expressing mCherry::SFTB-1 were anesthetized with 0.33 mM tetramisole hydrochlo-
ride and their heads cut using a pair of 25-gauge needles to extrude gonad arms. Released
gonads were fixed in 4% paraformaldehyde in PBS for 20–30 minutes and washed with PBS
+ 0.1% Tween 20 for 10 minutes. After performing 3 washes, gonads were transferred to a
microscope slide and mounted using 10 μl DAPI Fluoromount-G (SouthernBiotech). Images
were acquired the same day to avoid mCherry signal loss.
sftb-1 deletion mutant larval arrest quantification
Synchronized L1-arrested F2 worms from heterozygous sftb-1(cer6)/oxTi615 P0s were seeded
onto NGM plates with OP50 and imaged after 48 hours of growth at 20˚C using a ZEISS Axio
Observer Z1 inverted fluorescence microscope at 10X magnification. Body length was mea-
sured manually by drawing the midline of the worm using the freehand line tool in Fiji.
Phenotypic characterization
Similar experiments were conducted to characterize sftb-1[Q552P, R643C, K718E], rsp-4
[P100H], and uaf-2[S42F] mutant phenotypes. Briefly, synchronized L1-arrested worms of the
specified genotype were first seeded onto NGM plates with OP50 and, after a few hours to
allow recovery from the L1 arrest, 60 animals per genotype were separated individually to
12-well NGM plates seeded with OP50. Plates were incubated at 20˚C (Figs 4 and S3) or 25˚C
(Fig 1F–1H). The developmental stage of individual worms was assessed visually every 24
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hours under a stereomicroscope based on animal size and germline morphology. Phenotypes
were scored at day 4. In order to determine brood sizes of sftb-1[Q552P, R643C, K718E] and
WT animals, a proportion of worms were transferred into new 35-mm NGM plates at day 4
and subsequently moved to fresh plates every 12–24 h until egg laying ceased. Progeny were
counted 36–48 h after passages.
RNA isolation
To study the transcriptional consequences of the K718E mutation, we used two homozygous
mutant lines (CER218 and CER220) derived from two independent CRISPR/Cas9 events (cer3
and cer7 alleles, respectively), and the corresponding WT siblings (CER217 and CER221). Syn-
chronized L4 animals were collected in M9 after growing for 41 hours at 20˚C and total RNA
was isolated using TRI Reagent (MRC, Inc.) and the PureLink RNA Mini Kit (Ambion), fol-
lowing the manufacturer’s instructions.
sftb-1(cer6) homozygous larvae were obtained by automatically sorting non-red animals
from a synchronized CER191 population grown at 20˚C for 23 hours, using the COPAS Bio-
sorter system (Union Biometrica). We conducted two biological replicates with an average of
1.6% non-red recombinants and 5.25% red contaminants in the samples. The same size and
fluorescence window were used to sort two N2 WT populations collected under the same
experimental conditions. Two CER276 biological replicates were collected independently
without sorting, after growing for 23 hours at 20˚C. Total RNA from the six samples was
extracted using TRI Reagent, followed by aqueous and organic phase separation using
1-Bromo-3-chloropropane (Sigma-Aldrich), and RNA was precipitated with 2-propanol. After
treatment with TURBO DNase (Thermo Fisher Scientific), RNA was purified following a phe-
nol/chloroform extraction protocol.
In all cases, total RNA was quantified by Qubit RNA BR Assay kit (Thermo Fisher Scien-
tific) and the integrity was checked by using the Agilent RNA 6000 Nano Kit (Agilent).
RNA sequencing
Four RNA-seq libraries (from CER217, CER218, CER220, and CER221 strains) were prepared
with the KAPA Stranded mRNA-Seq Illumina Platforms Kit (Roche-Kapa Biosystems) follow-
ing the manufacturer’s recommendations. Briefly, 500 ng of total RNA was used as the input
material, the poly-A fraction was enriched with oligo-dT magnetic beads and the mRNA was
fragmented. Strand specificity was achieved during the second strand synthesis performed in
the presence of dUTP instead of dTTP. The blunt-ended double stranded cDNA was 3´adeny-
lated and Illumina indexed adapters from TruSeq™ Stranded Total RNA Sample Preparation
Kit with Ribo-Zero Gold (Illumina) were ligated.
The remaining six samples (two biological replicates from N2, CER276, and homozygous
sftb-1(cer6) larvae) were prepared using the TruSeq™ Stranded Total RNA kit protocol (Illu-
mina). Briefly, rRNA was depleted from 500 ng of total RNA using the Ribo-Zero Gold rRNA
Removal Kit and fragmented by divalent cations, with a major peak at 160 nt. Following the
fragmentation, first and second strand synthesis was performed, also ensuring the library
directionality. The cDNA was adenylated and ligated to xGen Dual Index UMI Adapters
(IDT) for paired-end sequencing.
Both types of library ligation products were enriched with 15 PCR cycles and the final
library was validated on an Agilent 2100 Bioanalyzer with the Agilent DNA 1000 Kit (Agilent).
The libraries were sequenced on HiSeq 2000 (Illumina) in paired-end mode with a read
length of 2x76 bp using the HiSeq SBS Kit V4 50 cycle kit in a fraction of a sequencing v4 flow
cell lane (HiSeq PE Cluster Kit V4—cBot). Image analysis, base calling, and quality scoring of
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the run were processed using the manufacturer’s software Real Time Analysis (RTA 1.18.66.3)
and followed by generation of FASTQ sequence files.
Bioinformatic analysis
RNA-seq reads were mapped against the C. elegans reference assembly (WBcel235.87) with
STAR [69]. Genes and transcripts were quantified with RSEM [70]. Differential expression
analysis was performed with DESeq2 R package [71], and detection of differential alternative
splicing events was done with rMATS [33].
RNAi screen
Information about the selected splicing genes was collected from SpliceosomeDB [72] or from
the literature. RNAi clones were obtained from the ORFeome library [73] or the Ahringer
library [28] and clone insert size was validated by PCR. For screening, we used 24-well plates
containing NGM supplemented with 50 μg/ml ampicillin, 12.5 μg/ml tetracycline and 3 mM
IPTG. Each well was seeded with 80 μl of bacterial culture and dsRNA expression was induced
overnight at room temperature. WT and mutant worms were tested in duplicates. Between 10
and 20 worms synchronized at the L1 stage were seeded in each well, and phenotypes were
scored visually at the adult stage (72–96 h post-seeding at 25˚C). Bacteria expressing dsRNA
against gfp were used as negative control. Screens in sftb-1[K718E] and sftb-1[R643C] back-
grounds were performed twice, at two different times, with different batches of plates and
RNAi cultures, and scored by two different persons. Several candidates were selected for fur-
ther validation, but the existence of false negatives in the screen is possible due to the noisy
nature of RNAi for essential genes in small plates.
Interaction between teg-4 and sftb-1 mutations
Worms of the indicated genotype were singled onto individual 35-mm NGM plates with OP50
at the L4 stage and transferred to new plates every 12 hours until all eggs were laid. Numbers
of dead embryos and hatched larvae were scored 24 and 48 hours after passages, respectively.
Since the double mutant sftb-1[K718E]; teg-4(oz210) could not be maintained in homozygosis,
F1 worms from sftb-1[K718E]; teg-4(oz210/+) P0 worms, including homozygous and heterozy-
gous animals for teg-4(oz210), were picked at the L4 stage and their progeny scored. These F1s
were genotyped after conducting the experiment to include only sftb-1[K718E] and sftb-1
[K718E]; teg-4(oz210) data.
Validation of candidates from the RNAi screen
In all cases, we used 55-mm or 35-mm NGM plates supplemented with 50 μg/mL ampicillin,
12.5 μg/mL tetracycline and 3 mM IPTG, seeded with specific RNAi bacterial clones. RNAi
targeting gfp was used as negative control and experiments were performed at 25˚C.
In Fig 3C and 3D and S6B Fig, synchronized L1-arrested worms of the indicated genotypes
were seeded onto 55-mm plates, and imaged directly on the plates after 48 hours of growth
using a stereomicroscope. Body length was determined automatically with WormSizer [74]. In
Fig 3E–3G, synchronized L1-arrested animals were seeded onto 55-mm plates and separated
into individual 35-mm plates at the L4 stage. Worms were transferred every 24 hours and the
presence of dead embryos was determined 24 hours after passages. In S6A Fig, synchronized
L1-arrested animals were seeded onto 55-mm plates and separated into individual wells in
24-well RNAi plates at the L4 stage, and the fertility phenotypes assessed in 2-day old adults.
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Number of germ cells assay
WT or sftb-1(cer6) homozygous worms were collected at the indicated time points, fixed using
Carnoy’s solution (60% absolute ethanol, 30% chloroform, 10% acetic acid), and washed three
times in PBS + 0.1% Tween 20. Whole worms were transferred to a microscope slide and
stained with DAPI Fluoromount-G in order to visualize and count germ cell nuclei.
Maternal product in sftb-1(cer6) homozygotes
In order to monitor the presence of mCherry::SFTB-1 maternal product, sftb-1(cer114) or sftb-
1(cer6/cer114) animals were separated blindly and allowed to lay eggs for 2, 9, and 12 hours in
three separate plates in order to semi-synchronize the F1 populations. Thus, only a fraction (23
hours) of the whole egg-laying period was covered. Red expression levels were assessed at dif-
ferent moments in order to include all the stages represented, which were designated visually
based on anatomic features. sftb-1(cer6/cer114) animals were distinguished from sftb-1(cer114)
animals by the presence of non-red arrested larvae in the next generation.
Semi-quantitative reverse-transcriptase PCR
N2, CER442, and CER450 animals grown at 20˚C were collected at the L2 (24 hours after seed-
ing L1-arrested worms) and adult stages. Total RNA was extracted using TRI Reagent, fol-
lowed by aqueous and organic phase separation using 1-Bromo-3-chloropropane (Sigma-
Aldrich), and RNA was precipitated with 2-propanol. After treatment with DNase I (Thermo
Fisher Scientific), cDNA was synthetized with the H Minus First Strand cDNA Synthesis Kit
(Thermo Fisher Scientific) following the manufacturer’s instructions. Primer sequences are
available upon request.
Spliceosome inhibitors experiments
Experiments in liquid media were conducted in 96-well plates. Experiments in S4 Table were
conducted as follows: 25 μl of dead OP50 resuspended in a mix of freshly prepared S Medium
[64], 4 μg/ml cholesterol, 250 μg/ml streptomycin, and 62.5 μg/ml tetracycline were added to
each well. Subsequently, 25 μl 2.4X drug and 10 μl L1-arrested worms at a density of 1–2
worms/μl were added to each well. Each condition was tested in duplicate in the same 96-well
plate. Plates were incubated in a humid chamber with gentle agitation at room temperature for
the indicated time period. 25 μl water (experiments 1–3) or 0.5% DMSO (Sigma-Aldrich)
(experiments 4 and 6) were used as negative controls. In experiment 5, 50 μM sudemycin D6
or 0.5% DMSO were injected into the gonads or intestine of young adult hermaphrodites
using standard microinjection techniques, and injected animals were recovered in individual
35-mm NGM plates with OP50 and incubated at 20˚C.
The protocol for liquid experiments in Fig 5C and 5D was slightly modified. In brief,
64.5 μl S Medium supplemented with 5 μg/ml cholesterol, 50 μg/ml streptomycin, and 50 μg/
ml ampicillin were added to each well. This supplemented S Medium was used to resuspend a
pellet of dead OP50 to an optical density of 1.1–1.2, and 25 μl of bacteria were dispensed to
each well. Subsequently, 10 μl L1-arrested worms at a density of 4–6 worms/μl, and 0.5 μl 200X
drug were added to each well. Each condition was tested in triplicate in the same 96-well plate.
Plates were incubated in a humid chamber at 25˚C.
Statistical analyses
In all figure legends, ‘N’ denotes the number of independent replicate experiments performed,
while ‘n’ indicates the total number of animals analyzed in each condition (different genotypes
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are separated by commas). Statistical analyses were performed in GraphPad Prism 6 and R.
Statistical tests used are reported in the figure legends. Figs 1A, 1D, 1F–1H, 2B–2D, 3B–3G, 4,
5C and 5D, and some panels in S2, S3, S4, S5 and S6 Figs were generated by using the ggplot2
R package.
Supporting information
S1 Fig. Most of the SF3B1 mutated residues are conserved in the C. elegans ortholog SFTB-
1. Protein sequence alignment of human SF3B1 (Hs) and worm SFTB-1 (Ce). The yellow his-
togram and the numerical index represent the degree of conservation (� corresponds to the
maximum degree of conservation). U2AF ligand motifs (ULMs), p14-interacting region and
HEAT domains are indicated in boxes. A cross symbol (X) below the conservation score indi-
cates positions where missense mutations have been reported in human cancers (COSMIC
database) at different frequencies. Residues that are relevant for this study are highlighted in
green.
(TIF)
S2 Fig. cer6 homozygotes inherit SFTB-1 maternal product. (A) Schematic representation of
the sftb-1 locus. Gray boxes indicate exons, connecting lines indicate introns. Left and right
orange boxes represent predicted 5’ and 3’ untranslated regions, respectively. In pink, 29
nucleotides that are deleted in the cer6 allele. Predicted amino acids resulting from translating
the WT or cer6 alleles are shown below the DNA sequence. The frameshift caused by the dele-
tion introduces a premature stop codon in the cer6 transcript (colored in red). Scale bar, 100
base pairs (bp). (B) Germ cell number of WT (N2 strain) or homozygous sftb-1(cer6) synchro-
nized larvae grown for 14, 23, and 40 hours at 20˚C. In WT worms, differentiating spermato-
cytes were not included at the last time point, and the number of germ cells was counted in
one gonad arm only. Black and gray lines connect the median germ cell number at each time
point in WT and sftb-1(cer6) worms, respectively. The dotted line represents the four germ
cells that are normally present in recently hatched L1 larvae; these cells will resume prolifera-
tion during the L1 stage. Between 2 and 10 animals per condition were scored (N = 1). (C)
Schematic representation of the compound heterozygous strain CER505: sftb-1(cer6)/sftb-1
(cer114[mCherry::sftb-1]) III. (D) Total number of progeny laid by heterozygous (cer6/+) or
WT (+/+) worms from a CER505 population (n = 7, 9; N = 1). The number of F1 larvae
expressing mCherry::SFTB-1 was not significantly different between both groups (n.s.), while
cer6/+ animals laid a significantly higher number of dead embryos which lacked red fluores-
cence (Mann-Whitney’s test; � p<0.05). Heterozygotes also segregated a number of non-red
larvae that were arrested and were not observed in WT plates, indicating that they were cer6/
cer6 animals. ‘+’ denotes the cer114[mCherry::sftb-1] allele. Dots represent measures in indi-
vidual worms, overlaid to Tukey-style boxplots. (E) Mean percentage of non-red F1 arrested
larvae (% Lva), F1 dead embryos (% Emb), and mean brood size in worms of the indicated
genotypes, from data represented in panel D. (F) mCherry::SFTB-1 expression in F1 progeny
from wild-type (top, n = 3) or heterozygous (bottom, n = 9) animals from a CER505 popula-
tion (N = 1). At each stage, vertical lines correspond to individual worms, and solid red, open
red, and black dots represent the total number of red, dim red, or non-red progeny observed,
respectively. Representative DIC and fluorescence microscopy images are shown below the
graph (scale bar, 25 μm). The mean percentage of dim red and non-red progeny laid by hetero-
zygotes is indicated in late stages and is not specified in early stages as it was 0%.
(TIF)
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S3 Fig. Molecular design of sftb-1 cancer-related mutations and sftb-1[Q552P, R643C,
K718E] phenotypes at 20˚C. (A) Schematic representation of the sftb-1 locus, as in S2 Fig.
The position of the triplets encoding the three mutated residues in this study (Q552, R643 and
K718) is indicated. Scale bar, 100 bp. (B) Molecular details of the three sftb-1 missense muta-
tions generated by CRISPR/Cas9. In WT alleles, the crRNA sequence used is indicated by
orange nucleotides, the protospacer-adjacent motif (PAM) is underlined and the Cas9 cut site
is indicated with a black arrowhead. In mutant alleles, synonymous mutations introduced to
prevent partial recombination events and to improve primer specificity for mutant allele detec-
tion by PCR are indicated in blue. Mutated codons and the corresponding amino acids are col-
ored in pink. (C) Bars represent mean incidence of different phenotypes observed in sftb-1
[Q552P, R643C, K718E] worms at 20˚C, while dots represent percentages observed in each
replicate (n = 116, 109; N = 2). (D) Brood size of WT or sftb-1[Q552P, R643C, K718E] worms
at 20˚C (n = 33, 46; N = 2). Dots represent values for each individual animal, overlaid to
Tukey-style boxplots. (E) sftb-1[Q552P, R643C, K718E] animals present a mild developmental
delay at 20˚C. Dot sizes represent the proportion of the population at each stage (n = 116, 109;
N = 2). Statistics: (C), Fisher’s exact test (D), Student’s t-test (unpaired, two-tailed). n.s., no sig-
nificant difference, ���� p<0.0001.
(TIF)
S4 Fig. Pathway enrichment analysis of genes with differentially expressed transcripts in
different sftb-1 mutant strains. Significantly enriched functional terms in the distinct datasets
are listed (padj<0.01). Bars represent the adjusted enrichment p-values in negative log10 scale,
color-coded by mutant strain. Solid and clear bars denote enriched terms in upregulated and
downregulated genes, respectively. The number of genes with differentially expressed tran-
scripts belonging to each category is shown. The analysis was performed with the g:GOSt tool
in g:Profiler, and only biological pathways from KEGG and WikiPathways databases are
shown.
(TIF)
S5 Fig. Common AS events deregulated by sftb-1 alleles. (A) Summary of the overlapping of
genes with AS changes (left) and the overlapping of AS events (right) between groups. (B)
Venn diagram displaying the overlapping AS events between the three datasets. The total num-
ber of significant events with inclusion level difference > 0.1 in each dataset is indicated. (C)
Plot showing the inclusion level difference (InclLevelDifference) of AS events that were dereg-
ulated in at least two datasets (‘common AS events’), color-coded according to the dataset. Dif-
ferent genes are represented along the x-axis, and events are separated by event type. Some
genes (acdh-2, fbn-1, Y69H2.3, unc-89, swp-1, and ate-1) shared more than one event in differ-
ent datasets.
(TIF)
S6 Fig. sftb-1(cer6) heterozygotes are sensitive to RNAi of five interactors. (A) mog-2
(RNAi), smr-1(RNAi), and teg-4(RNAi) cause a significant mild increase in sterility in sftb-1
(cer6) heterozygotes compared to WT at 25˚C (n�56; N = 2; � p<0.05, �� p<0.01, ����
p<0.0001; Fisher’s exact test). Red dots indicate percent sterility observed in each replicate.
Gray bars, P0-treated worms giving rise to<5 F1 larvae and some dead embryos (‘dead prog-
eny’ category); black bars, P0-treated worms that laid neither larvae nor dead embryos (‘no
progeny’ category). (B) sftb-1(RNAi) and uaf-2(RNAi) induce an earlier larval arrest in cer6/
+ heterozygous worms. Dots represent individual worm lengths after 48 h of RNAi treatment
at 25˚C, overlaid to Tukey-style boxplots (n�424; N = 2; ���� p<0.0001; Kruskal-Wallis test
with Dunn’s multiple comparison test). The genotype of the strain used for these experiments
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was CER190: sftb-1(cer6)/dpy-17(e164) unc-79(e1068) III.
(TIF)
S7 Fig. Effect of uaf-2[S42F] and rsp-4[P100H] mutations on a subset of AS events. (A)
cDNA samples from WT (N2), uaf-2[S42F], and rsp-4[P100H] worms at L2 and adult stage
were used to analyze the presence of alternative isoforms by semiquantitative (sq) RT-PCR
(N = 1). The alternative exons are numbered and shaded in gray in the schematic representa-
tion on the right, together with upstream and downstream exons where the forward and
reverse primers annealed, respectively. The three distinct isoforms in unc-32 E4 are indicated
with red lines on the left. act-1 was used as an endogenous control. (B) The 3’SS sequence of
the alternative exons is indicated, as well as the CCNG and GGNG motifs found in alternative
exons using FIMO with a p-value < 0.01. (C) Technical replicate of tos-1 E1-E2 and tos-1
E1-E4 sqRT-PCRs to verify that uaf-2[S42F] promotes intron 1 retention (slowest migrating
band in both gels) and exon 3 skipping (fastest migrating band in bottom gel), both indicated
with blue boxes. ‘E’ indicates exon, while ‘I’ indicates intron.
(TIF)
S1 Table. Alternative splicing analysis of sftb-1 mutants by rMATS.
(XLSX)
S2 Table. Differential expression analysis of sftb-1 mutants by DESeq2.
(XLSX)
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(XLSX)
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(XLSX)
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